{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:37:31Z","timestamp":1771853851767,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UH3HL123502"],"award-info":[{"award-number":["UH3HL123502"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["2P50AR060780"],"award-info":[{"award-number":["2P50AR060780"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01HL114453"],"award-info":[{"award-number":["P01HL114453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"United States Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Veterans Health Administration"},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Laboratory Research and Development"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","translationalres.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.trsl.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T18:50:21Z","timestamp":1522349421000},"page":"17-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis"],"prefix":"10.1016","volume":"198","author":[{"given":"Silke","family":"Meiners","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Evankovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-1593","authenticated-orcid":false,"given":"Rama K.","family":"Mallampalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2018.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0015","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","article-title":"Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers","volume":"24","author":"Barnes","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","article-title":"Incidence and prevalence of systemic sclerosis: a systematic literature review","volume":"37","author":"Chifflot","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semarthrit.2008.06.002","article-title":"Determinants of morbidity and mortality of systemic sclerosis in Canada","volume":"39","author":"Al-Dhaher","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2018.03.003_bib0040","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2018.03.003_bib0045","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor \u03b2\u2014at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-017-0630-3","article-title":"Innate immunity in systemic sclerosis","volume":"19","author":"Dowson","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.trsl.2018.03.003_bib0055","article-title":"Current perspectives on the immunopathogenesis of systemic sclerosis","volume":"21","author":"Fuschiotti","year":"2016","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.trsl.2018.03.003_bib0060","first-page":"96","article-title":"Fibrosis\u2014a common pathway to organ injury and failure","volume":"373","author":"Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.it.2005.09.004","article-title":"Scleroderma: from cell and molecular mechanisms to disease models","volume":"26","author":"Abraham","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/eci.11.40","article-title":"Novel insights on the role of the innate immune system in systemic sclerosis","volume":"7","author":"York","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/BOR.0b013e32832fd69e","article-title":"Innate immunity and inflammation in systemic sclerosis","volume":"21","author":"Lafyatis","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00281-015-0503-7","article-title":"Role of innate immune system in systemic sclerosis","volume":"37","author":"Fullard","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0090","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/art.23379","article-title":"Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model","volume":"58","author":"Hoyles","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease\u2014mechanisms and management","volume":"10","author":"Wells","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0100","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/rccm.201304-0754PP","article-title":"The emerging role of the ubiquitin proteasome in pulmonary biology and disease","volume":"188","author":"Weathington","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0105","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.cdd.4401692","article-title":"Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting","volume":"12","author":"Ciechanover","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.trsl.2018.03.003_bib0110","article-title":"The complexity of recognition of ubiquitinated substrates by the 26S proteasome","author":"Ciechanover","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2018.03.003_bib0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0125","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrm2468","article-title":"Diversity of degradation signals in the ubiquitin-proteasome system","volume":"9","author":"Ravid","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0130","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-145-9-200611070-00010","article-title":"Narrative review: protein degradation and human diseases: the ubiquitin connection","volume":"145","author":"Reinstein","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2018.03.003_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.sbi.2013.02.004","article-title":"The proteasome under the microscope: the regulatory particle in focus","volume":"23","author":"Lander","year":"2013","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0145","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0150","first-page":"1","article-title":"The immunoproteasome in antigen processing and other immunological functions","volume":"25","author":"Basler","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0155","doi-asserted-by":"crossref","first-page":"L328","DOI":"10.1152\/ajplung.00156.2016","article-title":"Proteasome function shapes innate and adaptive immune responses","volume":"311","author":"Kammerl","year":"2016","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2018.03.003_bib0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbamcr.2004.10.004","article-title":"The proteasome and MHC class I antigen processing","volume":"1695","author":"Kloetzel","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.trsl.2018.03.003_bib0170","first-page":"74","article-title":"The immunoproteasome: a novel drug target for autoimmune diseases","volume":"33","author":"Basler","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semcancer.2015.09.014","article-title":"Small molecule therapeutics targeting F-box proteins in cancer","volume":"36","author":"Liu","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0180","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/ni.2565","article-title":"A combinatorial F box protein directed pathway controls TRAF adaptor stability toregulate inflammation","volume":"14","author":"Chen","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0185","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2174\/0929867322666150209161224","article-title":"Molecular and cellular pathways as treatment targets for biologic therapies in systemic sclerosis","volume":"22","author":"Dimitroulas","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2016.10.022","article-title":"Therapeutic effects of a NEDD8-activating enzyme inhibitor, pevonedistat, on sclerodermatous graft-versus-host disease in mice","volume":"23","author":"Pai","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.trsl.2018.03.003_bib0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0200","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4161\/cc.23071","article-title":"F-box protein substrate recognition: a new insight","volume":"12","author":"Chen","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.trsl.2018.03.003_bib0205","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1042\/BCJ20160719","article-title":"Systematic approaches to identify E3 ligase substrates","volume":"473","author":"Iconomou","year":"2016","journal-title":"Biochem J"},{"key":"10.1016\/j.trsl.2018.03.003_bib0210","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug discovery in the ubiquitin-proteasome system","volume":"5","author":"Nalepa","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2018.03.003_bib0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.trsl.2018.03.003_bib0220","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.003_bib0225","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1089\/ars.2013.5823","article-title":"Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies","volume":"21","author":"Drews","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.trsl.2018.03.003_bib0230","article-title":"Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers","author":"Tsvetkov","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.003_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.08467","article-title":"Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome","volume":"4","author":"Tsvetkov","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.trsl.2018.03.003_bib0240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1515\/hsz-2012-0212","article-title":"Covalent and non-covalent reversible proteasome inhibition","volume":"393","author":"Beck","year":"2012","journal-title":"Biol Chem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome inhibitors: an expanding army attacking a unique target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0255","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1021\/jm500716s","article-title":"Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes","volume":"57","author":"de Bruin","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bjc.2012.243","article-title":"A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice","volume":"107","author":"Wehenkel","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.trsl.2018.03.003_bib0265","article-title":"Discovery of highly selective inhibitors of the immunoproteasome low molecular mass polypeptide 2 (LMP2) subunit","volume":"2","author":"Johnson","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.trsl.2018.03.003_bib0270","article-title":"Amelioration of autoimmunity with an inhibitor selectively targeting all active centers of the immunoproteasome","author":"Basler","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0275","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1089\/ars.2013.5816","article-title":"Harnessing proteasome dynamics and allostery in drug design","volume":"21","author":"Gaczynska","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.trsl.2018.03.003_bib0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"Brubaker","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0285","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2018.03.003_bib0290","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/annrheumdis-2015-207655","article-title":"Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms","volume":"75","author":"Connolly","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2018.03.003_bib0295","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.181.1.22","article-title":"Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A","volume":"181","author":"Cheng","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110820","article-title":"Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis","volume":"10","author":"Lakota","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.03.003_bib0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12260","article-title":"Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-\u03baB","volume":"143","author":"O'Reilly","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.trsl.2018.03.003_bib0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.33325","article-title":"A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators","volume":"64","author":"Broen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0315","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18496","article-title":"RING finger E3 ligase PPP1R11 regulates TLR2 signaling and innate immunity","volume":"5","author":"McKelvey","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.trsl.2018.03.003_bib0320","doi-asserted-by":"crossref","first-page":"232ra50","DOI":"10.1126\/scitranslmed.3008264","article-title":"Fibronectin EDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling","volume":"6","author":"Bhattacharyya","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0325","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/erm.2013.10","article-title":"Role of toll-like receptors in systemic sclerosis","volume":"15","author":"Ciechomska","year":"2013","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0330","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","article-title":"Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma","volume":"182","author":"Bhattacharyya","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","article-title":"Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis","volume":"67","author":"Takahashi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0340","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/ard.2009.128207","article-title":"Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis","volume":"69","author":"van Bon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2018.03.003_bib0345","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1066","article-title":"Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors","volume":"5","author":"Chuang","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0350","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature08780","article-title":"Circulating mitochondrial DAMPs cause inflammatory responses to injury","volume":"464","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2018.03.003_bib0355","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/art.39655","article-title":"Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor \u03b2-dependent fibroblast activation","volume":"68","author":"Fang","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0360","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/jid.2013.423","article-title":"Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma","volume":"134","author":"Farina","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0365","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri2687","article-title":"Proteasomes in immune cells: more than peptide producers?","volume":"10","author":"Groettrup","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00441-010-1018-0","article-title":"Pentraxins in innate immunity: lessons from PTX3","volume":"343","author":"Deban","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.trsl.2018.03.003_bib0375","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/eji.201545892","article-title":"The immunoproteasome controls the availability of the cardioprotective pattern recognition molecule Pentraxin3","volume":"46","author":"Paeschke","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0380","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.38953","article-title":"Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0385","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/cdd.2016.3","article-title":"Immunoproteasome dysfunction augments alternative polarization of alveolar macrophages","volume":"23","author":"Chen","year":"2016","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.trsl.2018.03.003_bib0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-13592-w","article-title":"Immunoproteasome subunit \u00df5i\/LMP7-deficiency in atherosclerosis","volume":"7","author":"Hewing","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2018.03.003_bib0395","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4049\/jimmunol.1400871","article-title":"Immunoproteasomes shape the transcriptome and regulate the function of dendritic cells","volume":"193","author":"de Verteuil","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0400","doi-asserted-by":"crossref","first-page":"50873","DOI":"10.18632\/oncotarget.15141","article-title":"Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice","volume":"8","author":"Koerner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trsl.2018.03.003_bib0405","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ni1090","article-title":"Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII","volume":"5","author":"Kloetzel","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0410","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ni.2203","article-title":"Mice completely lacking immunoproteasomes show major changes in antigen presentation","volume":"13","author":"Kincaid","year":"2012","journal-title":"Nat Immunol"},{"issue":"January","key":"10.1016\/j.trsl.2018.03.003_bib0415","doi-asserted-by":"crossref","first-page":"19434","DOI":"10.1038\/srep19434","article-title":"Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice","volume":"6","author":"Mundt","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.trsl.2018.03.003_bib0420","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clim.2016.07.018","article-title":"The proteasome\u2014victim or culprit in autoimmunity","volume":"172","author":"Feist","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0425","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm.1881","article-title":"Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis","volume":"14","author":"Friese","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0430","doi-asserted-by":"crossref","first-page":"18425","DOI":"10.1073\/pnas.0508621102","article-title":"Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes","volume":"102","author":"Pinkse","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.003_bib0435","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.4049\/jimmunol.1101003","article-title":"Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases","volume":"187","author":"Zaiss","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mehy.2011.10.010","article-title":"The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunity","volume":"78","author":"Eleftheriadis","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.trsl.2018.03.003_bib0445","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","article-title":"PSMB8 encoding the \u03b25i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome","volume":"87","author":"Agarwal","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.trsl.2018.03.003_bib0450","first-page":"4150","article-title":"A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0455","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0460","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1073\/pnas.1106015108","article-title":"Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome","volume":"108","author":"Arima","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.003_bib0465","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ijd.12695","article-title":"Proteasome-associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management","volume":"54","author":"McDermott","year":"2015","journal-title":"Int J Dermatol"},{"issue":"AUG","key":"10.1016\/j.trsl.2018.03.003_bib0470","first-page":"1","article-title":"CANDLE syndrome as a paradigm of proteasome-related autoinflammation","volume":"8","author":"Torrelo","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0475","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.21782","article-title":"Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sj\u00f6gren's syndrome","volume":"54","author":"Egerer","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0480","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.2005.045930","article-title":"Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders","volume":"65","author":"Krause","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2018.03.003_bib0485","doi-asserted-by":"crossref","first-page":"e9287","DOI":"10.1371\/journal.pone.0009287","article-title":"Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population","volume":"5","author":"Mishto","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.03.003_bib0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104048","article-title":"Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFN\u03b3","volume":"9","author":"Ghannam","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.03.003_bib0495","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of experimental colitis by a selective inhibitor of the immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0500","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1096\/fj.14-259333","article-title":"Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity","volume":"29","author":"Belogurov","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2018.03.003_bib0505","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.4049\/jimmunol.1201183","article-title":"Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation","volume":"189","author":"Kalim","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0510","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbpa.2014.08.012","article-title":"Subunit specific inhibitors of proteasomes and their potential for immunomodulation","volume":"23","author":"Kisselev","year":"2014","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0515","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1002\/anie.201509092","article-title":"A set of activity-based probes to visualize human (immuno)proteasome activities","volume":"55","author":"de Bruin","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.trsl.2018.03.003_bib0520","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.4049\/jimmunol.0903003","article-title":"Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses","volume":"184","author":"Hensley","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0525","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2018.03.003_bib0530","article-title":"Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation","author":"Li","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.trsl.2018.03.003_bib0535","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/ajt.14435","article-title":"The immunoproteasome: an old player with a novel and emerging role in alloimmunity","volume":"17","author":"Eskandari","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2018.03.003_bib0540","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.molimm.2017.05.022","article-title":"No prolongation of skin allograft survival by immunoproteasome inhibition in mice","volume":"88","author":"Mundt","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0545","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.14222","article-title":"Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings","volume":"17","author":"Ensor","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2018.03.003_bib0550","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","author":"Eskandary","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0555","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2016.07.003","article-title":"E3 ubiquitin ligase: a potential regulator in fibrosis and systemic sclerosis","volume":"306\u2013307","author":"Huang","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.trsl.2018.03.003_bib0565","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/art.11158","article-title":"Altered negative regulation of transforming growth factor beta signaling in scleroderma: potential involvement of SMURF2 in disease","volume":"48","author":"Zuscik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.trsl.2018.03.003_bib0570","doi-asserted-by":"crossref","first-page":"16736","DOI":"10.1073\/pnas.1412152111","article-title":"Peptide and small molecule inhibitors of HECT-type ubiquitin ligases","volume":"111","author":"Mund","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.trsl.2018.03.003_bib0575","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20151229","article-title":"Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4","volume":"213","author":"Lear","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2018.03.003_bib0580","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbrc.2004.04.161","article-title":"The RING domain of PIASy is involved in the suppression of bone morphogenetic protein-signaling pathway","volume":"319","author":"Imoto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.trsl.2018.03.003_bib0585","doi-asserted-by":"crossref","first-page":"34253","DOI":"10.1074\/jbc.M304961200","article-title":"Regulation of transforming growth factor-beta signaling by protein inhibitor of activated STAT, PIASy through Smad3","volume":"278","author":"Imoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trsl.2018.03.003_bib0590","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1096\/fj.05-4870fje","article-title":"Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts","volume":"20","author":"Fineschi","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2018.03.003_bib0595","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/01.HYP.0000142772.71367.65","article-title":"Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome","volume":"44","author":"Meiners","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.trsl.2018.03.003_bib0600","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/thoraxjnl-2011-200717","article-title":"Proteasomal inhibition after injury prevents fibrosis by modulating TGF-\u03b2(1) signalling","volume":"67","author":"Mutlu","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.trsl.2018.03.003_bib0605","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/med.20111","article-title":"Proteasome inhibitors: poisons and remedies","volume":"28","author":"Meiners","year":"2008","journal-title":"Med Res Rev"},{"key":"10.1016\/j.trsl.2018.03.003_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0136188","article-title":"Validation of the 2nd generation proteasome inhibitor oprozomib for local therapy of pulmonary fibrosis","volume":"10","author":"Semren","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.trsl.2018.03.003_bib0615","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1513\/pats.200906-055JS","article-title":"Proteasomal regulation of pulmonary fibrosis","volume":"7","author":"Weiss","year":"2010","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.trsl.2018.03.003_bib0620","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1164\/rccm.201412-2270OC","article-title":"Regulation of 26S proteasome activity in pulmonary fibrosis","volume":"192","author":"Semren","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524418300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T14:22:03Z","timestamp":1570976523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524418300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":123,"alternative-id":["S1931524418300501"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.003","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}